Key result
In rabbits with BSA nephritis, low-dose dipyridamole (2.5 mg/day) exacerbated the condition, significantly increasing mean proteinuria to 263 mg/day compared to 56 mg/day in controls, while a moderate dose (10 mg/day) resulted in mild glomerular changes.
Why the study?
Does dipyridamole improve histological and functional outcomes in BSA-induced nephritis in rabbits?
Does dipyridamole improve histological and functional outcomes in BSA-induced nephritis in rabbits?
Absolute Event Rate: 263% vs 56%
p-value: p=<0.05
In a rabbit model of BSA nephritis, moderate-dose dipyridamole may have beneficial effects on renal histology, whereas low-dose dipyridamole may exacerbate the condition.
No takes yet. Share an insight, caveat, or question.
Low-dose dipyridamole exacerbated proteinuria in this rabbit model; leaves open dose-dependent glomerular effects for translational study.
Ida et al. (1980) studied BSA nephritis (n=23). Dipyridamole vs. Non-treated control (BSA only) was evaluated on Proteinuria level (mg/day) (p=<0.05). In rabbits with BSA nephritis, low-dose dipyridamole (2.5 mg/day) exacerbated the condition, significantly increasing mean proteinuria to 263 mg/day compared to 56 mg/day in controls, while a moderate dose (10 mg/day) resulted in mild glomerular changes.
Synapse has enriched one closely related paper. Consider it for comparative context: